Bispecifics in Multiple Myeloma: Dosing and Transition of Care

A brief review of logistical considerations that play a part in selecting novel therapy for patients with multiply relapsed multiple myeloma.

Related Keywords

,Evolving Treatment Paradigm ,Multiple Myeloma ,Recent Updates ,Myeloma Cancer ,Relapsed Refractory Multiple Myeloma ,Multiply Relapsed ,Later Line Treatment ,Later Line Therapy ,Fixed Duration Therapy ,Duration Of Therapy ,Duration Of Treatment ,Step Up Dosing ,Priming Doses ,Dose Schedule ,Dosing Schedule ,Access To Care ,Healthcare Access ,Healthcare Equity ,Asco 2023 ,Asco Annual Meeting ,